Could Acute Pancreatitis Trigger Severe, Rapid-Onset Diabetes? New Chinese Cases Shed Light
Fulminant type 1 diabetes (FT1DM) is a rare, life-threatening form of diabetes where the pancreas’s insulin-making beta-cells are destroyed extremely quickly—often leading to ketoacidosis (a dangerous buildup of blood acids) within days of symptoms starting. Unlike typical type 1 diabetes, FT1DM usually doesn’t involve islet cell antibodies (proteins that attack the pancreas in autoimmune diabetes) and often shows elevated pancreatic enzymes. But what causes this sudden beta-cell collapse? A new study from China suggests a surprising link: acute pancreatitis (AP)—inflammation of the pancreas—may be a hidden trigger.
First Chinese Cases of FT1DM After Acute Pancreatitis
Researchers from the Department of Endocrinology at the Sixth Medical Center of PLA General Hospital in Beijing recently reported two cases of FT1DM developing shortly after mild AP—the first such cases documented in China. The findings, published in the Chinese Medical Journal in 2021, add to growing evidence from Japan that AP could play a role in FT1DM.
Case 1: A Fall, Pancreatitis, and Sudden Diabetes
A 40-year-old man developed abdominal pain after falling from a 2-meter platform in June 2017. His pain worsened with fever, and a CT scan revealed pancreatic swelling and fluid buildup—classic signs of AP. Blood tests showed elevated amylase (a pancreatic enzyme) and normal fasting blood sugar (4.96 mmol/L) initially. But just 6 days after his AP diagnosis, he became extremely thirsty, and his blood sugar spiked to 25.7 mmol/L—far above the diabetic threshold. Tests later showed undetectable C-peptide (a marker of insulin production), meaning his beta-cells were completely nonfunctional. He was diagnosed with FT1DM and started on insulin.
Case 2: Overeating, Pancreatitis, and Rapid Hyperglycemia
A 23-year-old man developed left upper abdominal pain after overeating. A CT scan confirmed AP, and initial blood sugar was normal (4.6 mmol/L). But within 5 days of his AP diagnosis, his blood sugar jumped from 8.1 mmol/L to 22 mmol/L in a single day. When he reached the hospital, his C-peptide levels were nearly undetectable, and his HbA1c (a 3-month blood sugar average) was only 7.9%—a sign his diabetes had started very recently. He, too, was diagnosed with FT1DM.
Both patients had mild AP (no severe pancreatic damage) but developed full-blown FT1DM within a week of their pancreatitis. Their pancreatic imaging later returned to normal, ruling out “pancreatogenic diabetes” (diabetes from permanent pancreatic injury). Instead, their rapid beta-cell loss matched the defining features of FT1DM.
What’s the Connection? Immune Response Overlap
The researchers propose that AP’s inflammatory immune response could trigger the same destructive cycle seen in FT1DM. Here’s the simplified breakdown:
When the pancreas is inflamed (AP), it releases inflammatory messengers like interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). These signals attract immune cells (T cells, macrophages) to the pancreas—normally to fight damage. But in people with genetic susceptibility to FT1DM, this immune response might mistakenly target the insulin-making islets.
In FT1DM, a similar cycle occurs: The pancreas releases a chemokine (CXCL10) that draws more immune cells to the islets. These cells release more IFN-γ, which damages beta-cells and makes surviving beta-cells produce even more CXCL10. It’s a vicious cycle that destroys beta-cells completely within days.
The study suggests AP’s immune response could kickstart this cycle. Japanese research supports this: In one study, 4 of 9 FT1DM patients had AP before their diabetes, and another found no islets left in a pancreas biopsy after AP. The inflammation from pancreatitis might be the “spark” that ignites the beta-cell destruction in FT1DM.
Genetic Susceptibility Matters
FT1DM is linked to specific genetic markers called HLA haplotypes—most commonly HLA-DRB104:05-DQB104:01. While the two Chinese patients had different HLA types, the researchers note that genetic susceptibility likely plays a role in who develops FT1DM after AP. More research is needed to identify which HLA markers increase risk.
What Does This Mean for Patients and Doctors?
These cases highlight a critical point: Sudden hyperglycemia after pancreatitis shouldn’t be dismissed as a temporary side effect. Doctors should monitor blood sugar closely in AP patients—especially if they have risk factors like genetic susceptibility or a history of autoimmune conditions. For patients, it’s a reminder that even “mild” pancreatitis could have severe, unexpected consequences.
The Takeaway
The study doesn’t prove AP causes FT1DM—but it provides strong evidence that AP may be a pathogenic factor. The researchers call for more animal studies and larger patient cohorts to confirm the link and understand the mechanism better.
For now, the findings add a new piece to the FT1DM puzzle. If confirmed, it could help doctors diagnose and treat FT1DM earlier—potentially saving lives by preventing ketoacidosis and permanent beta-cell loss.
Original study by Ya-Ning Chen, Ming-Wei Zhao, Jia Cui, and He-Bin Yao from the Department of Endocrinology, Sixth Medical Center of PLA General Hospital, Beijing, China. Published in the Chinese Medical Journal (2021;134(9):1127–1128).
References:
- Imagawa A, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. New England Journal of Medicine 2000;342:301–307. doi.org/10.1056/NEJM200002033420501
- Hirota H, et al. A case of fulminant type 1 diabetes patient accompanied by hyperinsulinemic hypoglycemia prior to clinical diagnosis of diabetes. Journal of the Japan Diabetes Society 2016;59:210–217. doi.org/10.11213/tonyobyo.59.210
- Miyagahara T, et al. Fulminant type 1 diabetes mellitus following acute pancreatitis and hypoglycemia with sequential imaging of the pancreas using computed tomography: a case report. Nihon Shokakibyo Gakkai Zasshi 2019;116:161–167.
- Wang Z, et al. Gene expression changes in patients with fulminant type 1 diabetes. Chinese Medical Journal 2011;123:3613–3617. doi.org/10.3760/cma.j.issn.0366-6999.2011.22.003
- Tanaka S, et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes 2009;58:2285–2291. doi.org/10.2337/db09-0091
doi.org/10.1097/CM9.0000000000001274
Was this helpful?
0 / 0